On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were underrepresented in COVID-19 treatment clinical trials, and some racial and ethnic groups were underrepresented in COVID-19 prevention trials.

The Fred Hutchinson Cancer Center in collaboration with researchers from Beijing and London identified system-wide differences in representation among several key demographic groups in COVID-19 prevention and treatment trials in the U.S. The study results were published in JAMA Internal Medicine.